Medicare’s Draft Policy For Alzheimer’s Drugs And The Question Of Cost

Critics of the US Centers for Medicare and Medicaid Services’ proposed decision to restrict Medicare coverage of Aduhelm and similar Alzheimer’s drugs have described the policy as an effort to ration treatments based on cost concerns. Even some supporters are connecting cost to the decision.

Should Cost Concerns Influence Medicare Coverage Policy? • Source: Alamy

US Medicare coverage policy is supposed to be fenced off from considerations about the cost of a prescription drug (or other item or service). But the notion that the cost of Biogen, Inc. and Eisai Co., Ltd.’s Aduhelm was a factor in Medicare’s proposed national coverage policy for Alzheimer’s drugs continues to surface in the debate over the policy.

The Centers for Medicare and Medicaid Services released a draft national coverage determination 11 January proposing that Medicare coverage for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet